Physician profile
Melissa M Hardt
NPI 1740635028
$615.75
in general payments reported to CMS, 2019-2025
13 companies · $616 in 2025
The $616 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $144.73 | 2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $66.37 | 2025 | Cologuard Collection Kit |
| Abiomed | $61.39 | 2025 | |
| Corcept Therapeutics | $58.08 | 2025 | Korlym |
| Lilly USA, LLC | $52.54 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.49 | 2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $45.61 | 2025 | Airsupra |
| Viatris Specialty LLC | $31.99 | 2025 | Yupelri |
| Neurocrine Biosciences, INC. | $31.80 | 2025 | |
| Abbott Laboratories | $21.17 | 2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $21.08 | 2025 | Inspire |
| Radius Health, INC. | $19.37 | 2025 | Tymlos |
| Glaxosmithkline, LLC. | $15.13 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Hardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.